BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tummala R, Abreu G, Pineda L, Michaels MA, Kalyani RN, Furie RA, Morand EF. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Sci Med 2021;8:e000464. [PMID: 33597205 DOI: 10.1136/lupus-2020-000464] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 23.0] [Reference Citation Analysis]
Number Citing Articles
1 Kalunian KC, Furie R, Morand EF, Bruce IN, Manzi S, Tanaka Y, Winthrop K, Hupka I, Zhang L(, Werther S, Abreu G, Hultquist M, Tummala R, Lindholm C, Al‐mossawi H. A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. Arthritis & Rheumatology 2022. [DOI: 10.1002/art.42392] [Reference Citation Analysis]
2 Rath E, Bonelli M, Duftner C, Gruber J, Mandl P, Moazedi-furst F, Pieringer H, Puchner R, Flick H, Salzer HJF, Weiss G, Winkler S, Skvara H, Moschen A, Hofer H, Feurstein J, Sautner J. Consensus Statement der Österreichischen Gesellschaften für Rheumatologie und Rehabilitation, Pneumologie, Infektiologie, Dermatologie und Gastroenterologie zum Umgang mit latenter Tuberkulose bei Therapien mit biologischen oder „targeted synthetic“ DMARDs („disease modifying antirheumatic drugs“). Z Rheumatol 2022. [DOI: 10.1007/s00393-022-01274-6] [Reference Citation Analysis]
3 Karonitsch T, Yeghiazaryan L, Lackner A, Brezinsek HP, Stamm TA, König F, Aletaha D, Smolen JS. Targeting type I interferon (IFN) signalling in patients with RA with a high type I IFN gene signature. RMD Open 2022;8:e002525. [PMID: 36270746 DOI: 10.1136/rmdopen-2022-002525] [Reference Citation Analysis]
4 Liu Z, Cheng R, Liu Y. Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review. Front Immunol 2022;13:996662. [DOI: 10.3389/fimmu.2022.996662] [Reference Citation Analysis]
5 Steiger S, Ehreiser L, Anders J, Anders H. Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials. Front Immunol 2022;13:999704. [DOI: 10.3389/fimmu.2022.999704] [Reference Citation Analysis]
6 Kirou KA, Dall`era M, Aranow C, Anders H. Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. Front Immunol 2022;13:980079. [DOI: 10.3389/fimmu.2022.980079] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Rath E, Bonelli M, Duftner C, Gruber J, Mandl P, Moazedi-Furst F, Pieringer H, Puchner R, Flick H, Salzer HJF, Weiss G, Winkler S, Skvara H, Moschen A, Hofer H, Feurstein J, Sautner J. National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs). Wien Klin Wochenschr 2022. [PMID: 36036323 DOI: 10.1007/s00508-022-02062-7] [Reference Citation Analysis]
8 Skácelová M. What is new in the treatment of Systemic Lupus Erythematosus? Vnitr Lek 2022;68:273-278. [DOI: 10.36290/vnl.2022.059] [Reference Citation Analysis]
9 Mathian A, Breillat P, Dorgham K, Bastard P, Charre C, Lhote R, Quentric P, Moyon Q, Mariaggi AA, Mouries-Martin S, Mellot C, Anna F, Haroche J, Cohen-Aubart F, Sterlin D, Zahr N, Gervais A, Le Voyer T, Bizien L, Amiot Q, Pha M, Hié M, Chasset F, Yssel H, Miyara M, Charneau P, Ghillani-Dalbin P, Casanova JL, Rozenberg F, Amoura Z, Gorochov G. Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α. Ann Rheum Dis 2022:annrheumdis-2022-222549. [PMID: 35973806 DOI: 10.1136/ard-2022-222549] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Lamb YN. Anifrolumab in systemic lupus erythematosus: a profile of its use. Drugs Ther Perspect 2022;38:293-300. [DOI: 10.1007/s40267-022-00925-7] [Reference Citation Analysis]
11 Bruce IN, Golam S, Steenkamp J, Wang P, Worthington E, Desta B, Psachoulia K, Erhardt W, Tummala R. Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. J Comp Eff Res 2022. [PMID: 35546484 DOI: 10.2217/cer-2022-0040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Puel A, Bastard P, Bustamante J, Casanova JL. Human autoantibodies underlying infectious diseases. J Exp Med 2022;219:e20211387. [PMID: 35319722 DOI: 10.1084/jem.20211387] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
13 Morand EF, Furie RA, Bruce IN, Vital EM, Dall'era M, Maho E, Pineda L, Tummala R. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. The Lancet Rheumatology 2022;4:e282-92. [DOI: 10.1016/s2665-9913(21)00317-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
14 Vital EM, Merrill JT, Morand EF, Furie RA, Bruce IN, Tanaka Y, Manzi S, Kalunian KC, Kalyani RN, Streicher K, Abreu G, Tummala R. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis 2022:annrheumdis-2021-221425. [PMID: 35338035 DOI: 10.1136/annrheumdis-2021-221425] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
15 Mak A. T Cells, Interleukin-2 and Systemic Lupus Erythematosus—From Pathophysiology to Therapy. Cells 2022;11:980. [DOI: 10.3390/cells11060980] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Jayne D, Rovin B, Mysler EF, Furie RA, Houssiau FA, Trasieva T, Knagenhjelm J, Schwetje E, Chia YL, Tummala R, Lindholm C. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis 2022:annrheumdis-2021-221478. [PMID: 35144924 DOI: 10.1136/annrheumdis-2021-221478] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 22.0] [Reference Citation Analysis]
17 Gulko HE, Furie R; Division of Rheumatology, Northwell Health, Great Neck, NY, USA, Division of Rheumatology, Northwell Health, Great Neck, NY, USA. Anifrolumab: An Inhibitor of Type I Interferon for the Treatment of Patients with Systemic Lupus Erythematosus. Rheumatology 2022;1:29. [DOI: 10.17925/rmd.2022.1.1.29] [Reference Citation Analysis]
18 Cooles FAH, Isaacs JD. The interferon gene signature as a clinically relevant biomarker in autoimmune rheumatic disease. The Lancet Rheumatology 2022;4:e61-72. [DOI: 10.1016/s2665-9913(21)00254-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
19 Nasonov EL, Avdeeva AS, Popkova TV. New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor). Naučno-praktičeskaâ revmatologiâ 2021;59:537-546. [DOI: 10.47360/1995-4484-2021-537-546] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Chia YL, Zhang J, Tummala R, Rouse T, Furie RA, Morand EF. Relationship of Anifrolumab Pharmacokinetics With Efficacy and Safety in Patients With Systemic Lupus Erythematosus. Rheumatology (Oxford) 2021:keab704. [PMID: 34528084 DOI: 10.1093/rheumatology/keab704] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
21 Nash A, Aghlara-Fotovat S, Hernandez A, Scull C, Veiseh O. Clinical translation of immunomodulatory therapeutics. Adv Drug Deliv Rev 2021;176:113896. [PMID: 34324885 DOI: 10.1016/j.addr.2021.113896] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]